Every 8-K that Si-Bone (SIBN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SIBN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SIBN filings page.
SI-BONE, Inc. reported second quarter 2026 results, with worldwide revenue of $56.0 million, up 15.2% from $48.6 million a year earlier. U.S. revenue was $53.2 million, up 14.7%, and international revenue $2.8 million, up 25.9%. Gross margin was 79.5% and gross profit $44.5 million.
Operating expenses rose to $49.4 million, but operating loss improved to $4.8 million and net loss narrowed to $4.1 million, or $0.09 per share. Adjusted EBITDA increased to $2.8 million from $1.0 million, and cash and equivalents were $145.9 million at June 30, 2026, with positive cash from operations of $0.8 million. Management raised 2026 worldwide revenue guidance to $231–$233 million (~15–16% growth), kept gross margin guidance at ~79%, and reduced expected operating expense growth to ~12%.
Operationally, active U.S. physicians reached 1,715, up 19%, and trailing 12‑month average revenue per territory rose 5% to $2.2 million. The company submitted a 510(k) application for a third breakthrough device, and CMS finalized a new MS‑DRG family with higher payments for procedures using iFuse Bedrock Granite in inpatient settings.
SI-BONE, Inc. entered into a Third Amendment to its headquarters office lease with BIXBY SPE FINANCE 11, LLC, extending the lease term for 21,848 square feet at 471 El Camino Real in Santa Clara. The amendment provides for a one‑month extension from August 1, 2026 to August 31, 2026 with base rent of $43,696 per month, plus the company’s share of operating expenses and taxes, and includes an option for an additional one‑month extension to September 30, 2026 on the same terms.
The company also held its Annual Meeting of Stockholders, with 38,905,031 shares represented, about 88% of the 44,243,715 shares outstanding and entitled to vote as of the April 6, 2026 record date. Stockholders elected two directors to terms ending at the 2029 annual meeting, ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers.
SI-BONE, Inc. reported strong first quarter 2026 results and raised its full-year 2026 outlook. Worldwide revenue grew 11.2% to $52.6 million, with U.S. revenue up 10.0% to $49.3 million and international revenue up 33.9% to $3.3 million.
Gross margin remained high at 79.8%, while net loss narrowed to $4.3 million or $0.10 per share, a 33.8% improvement from the prior year period. Adjusted EBITDA turned meaningfully higher to $2.5 million from $0.5 million, and cash and equivalents were $144.7 million as of March 31, 2026.
Management increased 2026 worldwide revenue guidance to $230–$233 million, implying approximately 14–16% growth, and raised the full-year gross margin expectation to about 79%, while reaffirming expectations for positive adjusted EBITDA.
SI-BONE, Inc. reported strong fourth quarter and full-year 2025 results with improving profitability and issued 2026 guidance. Worldwide revenue reached $56.3 million in Q4 2025, up 15.0%, and $200.9 million for 2025, up 20.2%, with gross margin near 79%.
Net loss narrowed to $1.6 million in Q4 and $18.9 million for 2025, while adjusted EBITDA turned positive at $5.1 million in Q4 and $8.9 million for the year. The company generated positive operating cash flow of $1.7 million and free cash flow of $0.4 million in Q4, ending 2025 with $147.8 million in cash and equivalents and $35.6 million in borrowings.
For 2026, SI-BONE guides to worldwide revenue of $228.5–$232.5 million, implying ~14–16% growth, with gross margin of about 78% and higher positive adjusted EBITDA. The company also signed a new long-term lease for larger facilities and promoted CFO Anshul Maheshwari to Chief Operating Officer.
SI-BONE, Inc. filed a current report describing that it has released a press release with preliminary unaudited revenue and cash and equivalents figures for the fourth quarter and full year 2025. These early numbers are meant to give the market an initial view of the company’s recent performance and year-end liquidity before audited results are available.
The company also plans meetings with investors and analysts, supported by a slide presentation. Both the press release and the presentation are included as exhibits and are being furnished, not filed, which means they are not automatically incorporated into other securities law filings.
SI-BONE, Inc. (SIBN) announced board and governance updates. Director Daniel Wolf resigned from the Board on November 6, 2025, and the company stated his resignation was not due to any disagreement with the company or management. Following his departure, the Board size was reduced from nine to eight, and current director Thomas A. West was appointed to the Audit Committee.
SI-BONE and Mr. Wolf entered into a 12-month consulting agreement covering marketing, strategy, business development and other corporate matters. The agreement accelerates vesting of 8,675 restricted stock units granted to Mr. Wolf on June 5, 2025, making them fully vested as of November 6, 2025, and provides cash compensation at an hourly rate set in applicable statements of work. The company also furnished a press release announcing results for the quarter ended September 30, 2025 as Exhibit 99.1.